Business Wire

EUNETWORKS

19.12.2022 09:31:42 CET | Business Wire | Press release

Share
euNetworks appoints Stephanie Lynch-Habib to President

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the appointment of Stephanie Lynch-Habib to the leadership team, taking up the role of President, euNetworks, with responsibility for all operating aspects of the business. This appointment is effective 15 January 2023. Stephanie’s appointment follows the recent announcement that Paula Cogan will take up the role of euNetworks’ Chief Executive Officer as Brady Rafuse moves to become euNetworks’ Chairman of the Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005195/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Stephanie Lynch-Habib (Photo: Business Wire)

Stephanie joins euNetworks following more than 25 years working in the telecom and technology industry. Most recently she was Chief Revenue Officer at InterCloud in Paris, responsible for driving growth opportunities for the business. Before joining InterCloud Stephanie led the global marketing and communications strategy of the GSMA, the global organisation representing mobile operators and organisations across the mobile ecosystem and adjacent industries. She has also held the position of Chief Marketing Officer at Colt, responsible for marketing strategy and prior to that, spent 16 years with AT&T EMEA, holding numerous senior marketing, sales, and strategy roles. While at AT&T, Stephanie was a founder of the AT&T European Women's Network. She has been recognised for her leading position in the sector, while also contributing to various women’s sector initiatives globally. Her global and European experience fit perfectly with the demands she will face as President at euNetworks.

“We are absolutely delighted to welcome Stephanie to euNetworks,” said Paula Cogan. “She’s a great addition to the team and fills a critical position in the business. I am excited for the contributions that Stephanie will make to euNetworks as I move to take up the role of Chief Executive Officer of euNetworks in January. Along with Stephanie’s global leadership experience, her advocacy, and efforts for strong women representation in the telecom sector is commendable and we welcome her contribution to euNetworks’ diversity and inclusion focus as well as in the wider industry.”

“Stephanie is a leader in the industry with extensive expertise, and she will be a great addition to the team,” said Cyrus Gentry, Managing Director and Head of Communications, Europe at Stonepeak. “Stephanie’s appointment is key to the strategic growth plan we are enacting at euNetworks, and we welcome her onboard and look forward to working with her.”

“I have watched the company develop and grow over the years with much admiration, and have worked with euNetworks as a customer most recently,” said Stephanie Lynch-Habib. “euNetworks’ reputation in the industry and among its customer base, who comprise the largest consumers of bandwidth in both Europe and globally, is exceptional. I am thrilled to be joining the team, and excited for the opportunity ahead for us all.”

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 490 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005195/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye